0001562180-20-001937.txt : 20200302 0001562180-20-001937.hdr.sgml : 20200302 20200302192924 ACCESSION NUMBER: 0001562180-20-001937 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200228 FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dahan Michel CENTRAL INDEX KEY: 0001669737 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 20679307 MAIL ADDRESS: STREET 1: C/O AKEBIA THERAPEUTICS, INC. STREET 2: 245 FIRST STREET, SUITE 1100 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-02-28 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001669737 Dahan Michel C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142 false true false false SVP, Chief Operating Officer Common Stock 2020-02-28 4 A false 65000.00 0.00 A 211932.00 D Common Stock 2020-02-28 4 S false 6972.00 8.70 D 204960.00 D Stock Option (Right to buy) 8.87 2020-02-28 4 A false 120000.00 0.00 A 2030-02-28 Common Stock 120000.00 120000.00 D The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. /s/ Nicole R. Hadas, attorney-in-fact for Michel Dahan 2020-03-02